Press release
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 35% Annual
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 35% Annual Growth (43% Using Constant Exchange Rate**) –\n\n– Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth –\n\n– Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.2 Billion –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches.\n\nPreliminary Fourth Quarter and Full Year 2022 Commercial and Financial Performance*\n\nTotal TTR: ONPATTRO® (patisiran) & AMVUTTRA® (vutrisiran)\n\n\nPreliminary global net product revenues for ONPATTRO and AMVUTTRA for the fourth quarter were approximately $122 million and $69 million, respectively, representing 12% total TTR quarterly growth compared to Q3 2022, and for the full year 2022 were approximately $558 million and $94 million, respectively, representing 37% total TTR annual growth compared to full year 2021.\n\n\nAs of year-end 2022, over 2,975 patients worldwide were receiving commercial ONPATTRO or AMVUTTRA.\n\n\nGIVLAARI® (givosiran)\n\n\nPreliminary global net product revenues for the fourth quarter and full year 2022 were approximately $47 million and $173 million, respectively, representing quarterly and annual growth of 3% and 35% compared to Q3 2022 and full year 2021, respectively.\n\n\nAs of year-end 2022, over 520 patients worldwide were receiving commercial GIVLAARI.\n\n\nOXLUMO® (lumasiran)\n\n\nPreliminary global net product revenues for the fourth quarter and full year 2022 were approximately $24 million and $70 million, respectively, representing quarterly and annual growth of 45% and 17% compared to Q3 2022 and full year 2021, respectively.\n\n\nAs of year-end 2022, over 280 patients worldwide were receiving commercial OXLUMO.\n\n\nFurther, at December 31, 2022, Alnylam had preliminary cash, cash equivalents, and marketable securities of approximately $2.2 billion, as compared to $2.4 billion at December 31, 2021.\n\n“We are pleased to have closed out 2022 on a very strong note with...